Potassium Canrenoate in Brain-dead Organ Donors: Randomized Controlled Clinical Trial
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
Given the current organ shortage, improving the quality/efficacy of harvested grafts from
expanded criteria donors is essential to substantially increase the number of potential
donors. Preclinical studies have shown that blocking the vascular mineralocorticoid receptor
(MR) mitigates ischemia-reperfusion injury (I/R) and prevents renal dysfunction following
acute kidney injury. Potassium canrenoate is an intravenous MR antagonist. Blocking the MR
upstream from aortic cross clamping is likely the most effective strategy to limit I/R
injury.
Yet, brain-dead donors are prone to severe hemodynamic instability and polyuria.
Consequently, this study seeks to assess the hemodynamic tolerance of the use of potassium
canrenoate in this context, as a first step to a large-scale clinical trial testing the
impact of this therapeutic intervention on the survival of kidney grafts.